Growth differentiation factor 8 (Myostatin) and Growth differentiation factor 11 (MSTN / GDF11)

Growth differentiation factor 8 (Myostatin) and Growth differentiation factor 11 (GDF-11) are secreted signaling proteins within the Transforming Growth Factor-beta (TGF-beta) superfamily that serve as critical regulators of tissue homeostasis (UniProt P54763; UniProt O95390). Myostatin is a well-characterized negative regulator of skeletal muscle mass; its deficiency leads to significant muscle hypertrophy, while its overexpression causes muscle wasting (Rodgers & Garikipati, Endocrine Reviews, 2008). GDF-11 is structurally similar to myostatin but exhibits a wider expression pattern, influencing erythropoiesis, skeletal development, and potentially aging processes (Suragani et al., Nature Medicine, 2014). Both ligands signal through a complex involving Activin type II receptors (ActRIIA and ActRIIB) and type I receptors (ALK4/5/7), leading to the activation of the Smad2/3 pathway (Attisano & Wrana, Science, 2002). In clinical practice, these ligands are targeted to treat conditions such as sarcopenia, muscular dystrophy, and cachexia by promoting muscle growth. Additionally, ligand traps like luspatercept and sotatercept, which bind GDF-11 and related ligands, are used to treat anemia in beta-thalassemia and pulmonary arterial hypertension by modulating erythroid maturation and vascular remodeling (Markham, Drugs, 2020; Hoeper et al., NEJM, 2023).

Other names

MyostatinGDF-8GDF-11Bone morphogenetic protein 11BMP-11Growth differentiation factor 8

Inhibition of signaling by sequestering ligands (GDF-8/GDF-11) using decoy receptors (ligand traps), neutralizing ligands with monoclonal antibodies, or preventing the proteolytic activation of pro-forms to block binding to Activin type II receptors (ActRIIA/B) and subsequent Smad2/3 phosphorylation.